NCT04087096View on ClinicalTrials.gov

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

August 6, 2024

Study Completion Date

August 6, 2024

Conditions
Bariatric Surgery CandidateBone Loss
Interventions
DRUG

Denosumab

Denosumab will be administered at postoperative months 1, 7, and 13

DRUG

Placebo

Placebo will be administered at postoperative months 1, 7, and 13

DRUG

Zoledronic Acid

Zoledronic Acid 5mg will be administered intravenously at postoperative month 19

Trial Locations (2)

94143

University of California, San Francisco, San Francisco

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

University of California, San Francisco

OTHER

collaborator

San Francisco VA Health Care System

FED

lead

Massachusetts General Hospital

OTHER

NCT04087096 - Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery | Biotech Hunter | Biotech Hunter